메뉴 건너뛰기




Volumn 54, Issue 5, 2013, Pages 1168-1177

Prognostic factors for patients with bone-only metastasis in breast cancer

Author keywords

Bisphosphonate; Bone metastses; Breast neoplasm

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; PAMIDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

EID: 84880976794     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.5.1168     Document Type: Article
Times cited : (93)

References (39)
  • 2
    • 0029759541 scopus 로고    scopus 로고
    • Annual hazard rates of recurrence for breast cancer after primary therapy
    • Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
    • (1996) J Clin Oncol , vol.14 , pp. 2738-2746
    • Saphner, T.1    Tormey, D.C.2    Gray, R.3
  • 3
    • 0034097586 scopus 로고    scopus 로고
    • Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis
    • Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59: 271-8.
    • (2000) Breast Cancer Res Treat , vol.59 , pp. 271-278
    • Solomayer, E.F.1    Diel, I.J.2    Meyberg, G.C.3    Gollan, C.4    Bastert, G.5
  • 4
    • 84928099132 scopus 로고    scopus 로고
    • Surveillance of patients following primary therapy
    • In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors, 4th ed. Philadelphia: Lippincott Wil&Wilkins
    • Robert WC. Surveillance of patients following primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Disease of the breast. 4th ed. Philadelphia: Lippincott Wil&Wilkins; 2009. p.823-31.
    • (2009) Disease of the Breast , pp. 823-831
    • Robert, W.C.1
  • 5
    • 0022535311 scopus 로고
    • Metastatic breast cancer confined to the skeletal system. An indolent disease
    • Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81:381-6.
    • (1986) Am J Med , vol.81 , pp. 381-386
    • Sherry, M.M.1    Greco, F.A.2    Johnson, D.H.3    Hainsworth, J.D.4
  • 6
    • 0022860180 scopus 로고
    • Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy
    • Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58:2589-93.
    • (1986) Cancer , vol.58 , pp. 2589-2593
    • Scheid, V.1    Buzdar, A.U.2    Smith, T.L.3    Hortobagyi, G.N.4
  • 7
    • 0034051908 scopus 로고    scopus 로고
    • Risk of complications from bone metastases in breast cancer. Implications for management
    • Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000;36:476-82.
    • (2000) Eur J Cancer , vol.36 , pp. 476-482
    • Plunkett, T.A.1    Smith, P.2    Rubens, R.D.3
  • 8
    • 0034661681 scopus 로고    scopus 로고
    • Predictors of skeletal complications in patients with metastatic breast carcinoma
    • Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363-8.
    • (2000) Cancer , vol.89 , pp. 363-368
    • Domchek, S.M.1    Younger, J.2    Finkelstein, D.M.3    Seiden, M.V.4
  • 9
    • 0031964897 scopus 로고    scopus 로고
    • Clinical course and prognostic factors following bone recurrence from breast cancer
    • Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40.
    • (1998) Br J Cancer , vol.77 , pp. 336-340
    • Coleman, R.E.1    Smith, P.2    Rubens, R.D.3
  • 10
    • 79952609466 scopus 로고    scopus 로고
    • Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: A single-institution retrospective analysis
    • Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist 2011;16:155-64.
    • (2011) Oncologist , vol.16 , pp. 155-164
    • Niikura, N.1    Liu, J.2    Hayashi, N.3    Palla, S.L.4    Tokuda, Y.5    Hortobagyi, G.N.6
  • 11
    • 0037301972 scopus 로고    scopus 로고
    • Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor
    • Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97:545-53.
    • (2003) Cancer , vol.97 , pp. 545-553
    • Chang, J.1    Clark, G.M.2    Allred, D.C.3    Mohsin, S.4    Chamness, G.5    Elledge, R.M.6
  • 12
    • 0041508749 scopus 로고    scopus 로고
    • Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients
    • Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-40.
    • (2003) Ann Oncol , vol.14 , pp. 1234-1240
    • Koizumi, M.1    Yoshimoto, M.2    Kasumi, F.3    Ogata, E.4
  • 13
    • 0043236248 scopus 로고    scopus 로고
    • Bone metastases from breast carcinoma: Histopathologicalradiological correlations and prognostic features
    • James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, et al. Bone metastases from breast carcinoma: histopathologicalradiological correlations and prognostic features. Br J Cancer 2003;89:660-5.
    • (2003) Br J Cancer , vol.89 , pp. 660-665
    • James, J.J.1    Evans, A.J.2    Pinder, S.E.3    Gutteridge, E.4    Cheung, K.L.5    Chan, S.6
  • 14
    • 84859645793 scopus 로고    scopus 로고
    • Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
    • Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 2012;118:2039-47.
    • (2012) Cancer , vol.118 , pp. 2039-2047
    • Niikura, N.1    Liu, J.2    Hayashi, N.3    Palla, S.L.4    Tokuda, Y.5    Hortobagyi, G.N.6
  • 16
    • 0023145358 scopus 로고
    • Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients
    • Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
    • (1987) J Clin Oncol , vol.5 , pp. 55-61
    • Clark, G.M.1    Sledge Jr., G.W.2    Osborne, C.K.3    McGuire, W.L.4
  • 18
    • 0032189117 scopus 로고    scopus 로고
    • Treatment of breast cancer
    • Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
    • (1998) N Engl J Med , vol.339 , pp. 974-984
    • Hortobagyi, G.N.1
  • 19
    • 0023858669 scopus 로고
    • Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses
    • Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 1988;6:89-97.
    • (1988) J Clin Oncol , vol.6 , pp. 89-97
    • Goldhirsch, A.1    Gelber, R.D.2    Castiglione, M.3
  • 20
    • 0036710434 scopus 로고    scopus 로고
    • Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women
    • Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjövall M, Fornander T, et al. Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer 2002;38:1860-70.
    • (2002) Eur J Cancer , vol.38 , pp. 1860-1870
    • Fredriksson, I.1    Liljegren, G.2    Arnesson, L.G.3    Emdin, S.O.4    Palm-Sjövall, M.5    Fornander, T.6
  • 21
    • 0034162528 scopus 로고    scopus 로고
    • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
    • Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
    • (2000) Cancer , vol.88 , pp. 1082-1090
    • Lipton, A.1    Theriault, R.L.2    Hortobagyi, G.N.3    Simeone, J.4    Knight, R.D.5    Mellars, K.6
  • 22
    • 0033050818 scopus 로고    scopus 로고
    • Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
    • Protocol 18 Aredia Breast Cancer Study Group
    • Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
    • (1999) J Clin Oncol , vol.17 , pp. 846-854
    • Theriault, R.L.1    Lipton, A.2    Hortobagyi, G.N.3    Leff, R.4    Glück, S.5    Stewart, J.F.6
  • 23
    • 10544228130 scopus 로고    scopus 로고
    • Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
    • Protocol 19 Aredia Breast Cancer Study Group
    • Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
    • (1996) N Engl J Med , vol.335 , pp. 1785-1791
    • Hortobagyi, G.N.1    Theriault, R.L.2    Porter, L.3    Blayney, D.4    Lipton, A.5    Sinoff, C.6
  • 24
    • 7144223389 scopus 로고    scopus 로고
    • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
    • Protocol 19 Aredia Breast Cancer Study Group
    • Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
    • (1998) J Clin Oncol , vol.16 , pp. 2038-2044
    • Hortobagyi, G.N.1    Theriault, R.L.2    Lipton, A.3    Porter, L.4    Blayney, D.5    Sinoff, C.6
  • 25
    • 10744233992 scopus 로고    scopus 로고
    • Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    • Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
    • (2004) Cancer , vol.100 , pp. 36-43
    • Rosen, L.S.1    Gordon, D.H.2    Dugan Jr., W.3    Major, P.4    Eisenberg, P.D.5    Provencher, L.6
  • 26
    • 0042914647 scopus 로고    scopus 로고
    • Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    • Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
    • (2003) J Clin Oncol , vol.21 , pp. 3150-3157
    • Rosen, L.S.1    Gordon, D.2    Tchekmedyian, S.3    Yanagihara, R.4    Hirsh, V.5    Krzakowski, M.6
  • 27
    • 0035463593 scopus 로고    scopus 로고
    • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
    • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
    • (2001) Cancer J , vol.7 , pp. 377-387
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3    Howell, A.4    Belch, A.5    Mackey, J.6
  • 28
    • 10744233021 scopus 로고    scopus 로고
    • Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
    • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
    • (2003) Cancer , vol.98 , pp. 1735-1744
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3    Howell, A.4    Belch, A.5    Mackey, J.6
  • 29
    • 10744227993 scopus 로고    scopus 로고
    • Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
    • Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
    • (2003) Clin Cancer Res , vol.9 , pp. 2893-2897
    • Santini, D.1    Vincenzi, B.2    Dicuonzo, G.3    Avvisati, G.4    Massacesi, C.5    Battistoni, F.6
  • 30
    • 0035917560 scopus 로고    scopus 로고
    • The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
    • Jagdev SP, Coleman RE, Shipman CM, Rostami H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
    • (2001) Br J Cancer , vol.84 , pp. 1126-1134
    • Jagdev, S.P.1    Coleman, R.E.2    Shipman, C.M.3    Rostami, H.A.4    Croucher, P.I.5
  • 31
    • 33646107396 scopus 로고    scopus 로고
    • Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro
    • Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103.
    • (2006) Tumour Biol , vol.27 , pp. 92-103
    • Neville-Webbe, H.L.1    Evans, C.A.2    Coleman, R.E.3    Holen, I.4
  • 33
    • 56749165071 scopus 로고    scopus 로고
    • Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up
    • Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11.
    • (2008) Ann Oncol , vol.19 , pp. 2007-2011
    • Diel, I.J.1    Jaschke, A.2    Solomayer, E.F.3    Gollan, C.4    Bastert, G.5    Sohn, C.6
  • 34
    • 9444254706 scopus 로고    scopus 로고
    • Ten-year fol-low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
    • Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year fol-low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650-6.
    • (2004) Acta Oncol , vol.43 , pp. 650-656
    • Saarto, T.1    Vehmanen, L.2    Virkkunen, P.3    Blomqvist, C.4
  • 35
    • 77954580167 scopus 로고    scopus 로고
    • Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
    • Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188-94.
    • (2010) Ann Oncol , vol.21 , pp. 2188-2194
    • Eidtmann, H.1    de Boer, R.2    Bundred, N.3    Llombart-Cussac, A.4    Davidson, N.5    Neven, P.6
  • 36
    • 84655169571 scopus 로고    scopus 로고
    • The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
    • Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012;48:187-95.
    • (2012) Eur J Cancer , vol.48 , pp. 187-195
    • Yan, T.1    Yin, W.2    Zhou, Q.3    Zhou, L.4    Jiang, Y.5    Du, Y.6
  • 39
    • 67649818458 scopus 로고    scopus 로고
    • Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases
    • Park IH, Ro J, Nam BH, Kwon Y, Lee KS. Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer 2009;9:154.
    • (2009) BMC Cancer , vol.9 , pp. 154
    • Park, I.H.1    Ro, J.2    Nam, B.H.3    Kwon, Y.4    Lee, K.S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.